5/30
04:01 pm
krro
Korro to Participate in Upcoming June Investor and Scientific Conferences
Low
Report
Korro to Participate in Upcoming June Investor and Scientific Conferences
5/21
08:03 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
5/20
03:54 pm
krro
Forbion-backed biotech Progentos debuts with $65M for MS drug [Yahoo! Finance]
Low
Report
Forbion-backed biotech Progentos debuts with $65M for MS drug [Yahoo! Finance]
5/20
02:30 pm
krro
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
Low
Report
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
5/15
12:25 pm
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at HC Wainwright from $115.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at HC Wainwright from $115.00 to $100.00. They now have a "buy" rating on the stock.
5/15
09:18 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.
5/14
04:01 pm
krro
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
Medium
Report
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
5/7
07:16 am
krro
Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer [Yahoo! Finance]
Low
Report
Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer [Yahoo! Finance]
4/18
08:30 am
krro
Korro Announces $70 Million Private Placement
Low
Report
Korro Announces $70 Million Private Placement
4/1
04:01 pm
krro
Korro to Participate in Upcoming Investor Conferences
Medium
Report
Korro to Participate in Upcoming Investor Conferences
3/28
08:07 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a "buy" rating on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a "buy" rating on the stock.
3/27
01:09 pm
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.
3/27
10:56 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at Royal Bank of Canada from $70.00 to $90.00. They now have an "outperform" rating on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at Royal Bank of Canada from $70.00 to $90.00. They now have an "outperform" rating on the stock.
3/26
04:01 pm
krro
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
Low
Report
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
3/26
08:11 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.
High
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.